コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 aled them as being similar to the endogenous indoleamine.
2 lation of circulating prostaglandin E(2) and indoleamine 2, 3,-dioxygenase enzymatic activity, as wel
3 HS suppressed mRNA and protein expression of indoleamine 2, 3-dioxygenase (IDO) and its activity upon
5 recently shown that expression of the enzyme indoleamine 2, 3-dioxygenase (IDO) during murine pregnan
7 y modulating the expression of PD-L1; Tim-3; indoleamine 2, 3-dioxygenase (IDO); and interleukin 10.
10 ly produced by both cell populations, unlike indoleamine 2, 3-dioxygenase which was only produced fol
12 , depletion of Gr1(+) cells or inhibition of indoleamine 2,3 dioxygenase (IDO) activity abrogates gra
15 amino acid TRP, cells expressing the enzyme indoleamine 2,3 dioxygenase (IDO) can mediate potent loc
18 d expression of the immune regulatory enzyme indoleamine 2,3 dioxygenase (IDO) in local lymph nodes.
20 xpression of the tryptophan-degrading enzyme indoleamine 2,3 dioxygenase (IDO) is selectively induced
21 ha(-/-) mice was likely because of a lack of indoleamine 2,3 dioxygenase (IDO), a critical regulator
22 e expression of interferon-gamma (IFNgamma), indoleamine 2,3 dioxygenase (IDO), and human leukocyte a
23 local draining lymph nodes (dLNs) to express indoleamine 2,3 dioxygenase (IDO), which confers T cell
24 aneously, pDCs up-regulate the expression of indoleamine 2,3 dioxygenase (IDO), which is essential fo
28 endent on the tryptophan catabolizing enzyme indoleamine 2,3 dioxygenase 1 (IDO1) in splenic macropha
30 , the SE inhibited the enzymatic activity of indoleamine 2,3 dioxygenase, a key enzyme in immune tole
36 factor alpha (TNF-alpha) and upregulation of indoleamine 2,3-deoxygenase (IDO) but not of Toll-like r
38 physiological importance of human placental indoleamine 2,3-dioxygenase (EC 1.13.11.42), the first a
39 that inhibition of enzyme activity in human indoleamine 2,3-dioxygenase (hIDO) and a number of site-
42 han 2,3 dioxygenase (hTDO), and the other is indoleamine 2,3-dioxygenase (hIDO), both of which cataly
43 nt in heme-based dioxygenases, such as human indoleamine 2,3-dioxygenase (hIDO), was not recognized u
47 ther gamma interferon (IFN-gamma) can induce indoleamine 2,3-dioxygenase (IDO) activity in aortic smo
48 higher levels of gamma interferon-inducible indoleamine 2,3-dioxygenase (IDO) activity than endothel
49 ike receptor (TLR) 4 signaling, can regulate indoleamine 2,3-dioxygenase (IDO) activity, favoring TH2
52 describe a subset of human APCs that express indoleamine 2,3-dioxygenase (IDO) and inhibit T cell pro
53 h a focus on the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO) and its recently disco
54 ltiple immune inhibitory molecules including indoleamine 2,3-dioxygenase (IDO) and programmed cell de
55 inhibitory effect was primarily mediated by indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (
56 omotes immune suppression through the enzyme indoleamine 2,3-dioxygenase (IDO) and subsequent product
57 tivated inflammatory macrophages can express indoleamine 2,3-dioxygenase (IDO) and thus actively depl
59 ortage of tryptophan caused by expression of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dio
60 eprogramming was suppressed by tumor-induced indoleamine 2,3-dioxygenase (IDO) and vaccination failed
65 aneous efficacy of serum and urine biomarker indoleamine 2,3-dioxygenase (IDO) enzyme activity and pe
66 CR analysis revealed a 5-fold enhancement of indoleamine 2,3-dioxygenase (IDO) expression in the tumo
69 vation of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) in cancer cells facili
70 ously shown that an immunomodulatory enzyme, indoleamine 2,3-dioxygenase (IDO) in dermal fibroblasts
71 rucial role for the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) in GVHD regulation.
72 tent to express the T-cell regulatory enzyme indoleamine 2,3-dioxygenase (IDO) in mice treated with T
73 upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs an
74 critical role for the immune escape mediator indoleamine 2,3-dioxygenase (IDO) in supporting inflamma
75 Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can fac
76 n 4 (CTLA-4) blockade and treatment with the indoleamine 2,3-dioxygenase (IDO) inhibitor 1-methyl-D-t
77 n a prodrug conjugate of PEG with NLG919, an indoleamine 2,3-dioxygenase (IDO) inhibitor currently us
78 nt and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenase (IDO) inhibitors, inhibitors
86 bolism of the amino acid tryptophan (Trp) by indoleamine 2,3-dioxygenase (IDO) is considered an impor
91 y, expression of the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is induced following i
101 ors of the tryptophan (Trp) catabolic enzyme indoleamine 2,3-dioxygenase (IDO) represent a vanguard o
103 s study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on c
106 In contrast, we found that the induction of indoleamine 2,3-dioxygenase (IDO) was required for the a
107 the tolerogenic tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) were analyzed using fl
109 ithelial infection by inducing expression of indoleamine 2,3-dioxygenase (IDO), a host enzyme with pr
110 sed antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic enz
112 duct brassinin to be a moderate inhibitor of indoleamine 2,3-dioxygenase (IDO), a new cancer immunosu
114 Br-brassinin) are bioavailable inhibitors of indoleamine 2,3-dioxygenase (IDO), a pro-toleragenic enz
115 s to HDAC inhibitors increased expression of indoleamine 2,3-dioxygenase (IDO), a suppressor of DC fu
116 through pathogen-specific local induction of indoleamine 2,3-dioxygenase (IDO), a tryptophan cataboli
117 re treated with a pharmacologic inhibitor of indoleamine 2,3-dioxygenase (IDO), a tryptophan-cataboli
118 ad7-deficient DCs expressed higher levels of indoleamine 2,3-dioxygenase (IDO), an enzyme associated
119 at M. tuberculosis induced the expression of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in
121 Similar to CTLA-4 and FoxP3, expression of indoleamine 2,3-dioxygenase (IDO), an immunosuppressive
123 sing T cells (CARTs) through the activity of indoleamine 2,3-dioxygenase (IDO), an intracellular enzy
124 nzymes, tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO), during its conversion
125 l-molecule immunotherapy agent that inhibits indoleamine 2,3-dioxygenase (IDO), encapsulated in the n
126 yptophan catabolism, initiated by the enzyme indoleamine 2,3-dioxygenase (IDO), is a critical partici
127 Although the tryptophan-degrading enzyme, indoleamine 2,3-dioxygenase (IDO), is a pivotal mediator
128 analytes-including plasma concentrations of indoleamine 2,3-dioxygenase (IDO), KYN, kynurenic acid (
129 ted reduced toxicity as reflected by induced indoleamine 2,3-dioxygenase (IDO), suggesting discreet a
130 induce an IFNgamma-driven induction of host indoleamine 2,3-dioxygenase (IDO), the first and rate-li
133 n of innate immunity, induces high levels of indoleamine 2,3-dioxygenase (IDO), the rate-limiting enz
135 f expressing the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO), which allows them to
137 C production of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO), which depletes local
138 ations of RV-PV dysfunction with circulating indoleamine 2,3-dioxygenase (IDO)-dependent tryptophan m
139 ptophan oxidation products produced from the indoleamine 2,3-dioxygenase (IDO)-mediated kynurenine pa
152 use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunos
154 ession of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO1) in human epithelial c
159 he anti-inflammatory and anti-bacterial gene indoleamine 2,3-dioxygenase (IDO1) is dependent on STAT1
164 ses of two antiretroviral ISGs indicate that indoleamine 2,3-dioxygenase 1 (IDO1) can inhibit retrovi
166 as driven by IFN-gamma-mediated induction of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme activity wit
167 ession of the tryptophan metabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1) in the intestinal e
171 ding l-kynurenine (Kyn), the main product of indoleamine 2,3-dioxygenase 1 (IDO1) that catalyzes the
172 d that S. flexneri induces the expression of indoleamine 2,3-dioxygenase 1 (IDO1) through the nucleot
174 tion, a host tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase 1 (IDO1), is induced specifi
176 s along the kynurenine pathway by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which is induced b
182 hermore, treatment of NKp44(+) NK cells with indoleamine 2,3-dioxygenase 1 catabolites in vitro ablat
189 cts of gamma interferon (IFN-gamma)-mediated indoleamine 2,3-dioxygenase activity on C. pneumoniae pe
191 lls express high levels of CD163, CD206, and indoleamine 2,3-dioxygenase and secrete immunosuppressiv
192 grafts and increased expression of mRNAs for indoleamine 2,3-dioxygenase and the subunits encoding in
193 is an O2-dependent process and catalyzed by indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygena
200 In human epithelial cells, IFN-gamma induces indoleamine 2,3-dioxygenase expression that inhibits chl
201 feron-gamma, which increases villous explant indoleamine 2,3-dioxygenase expression, has no effect on
203 f AhR ligands by microbiota that could limit indoleamine 2,3-dioxygenase induction and influence allo
205 Abnormal tryptophan metabolism catalyzed by indoleamine 2,3-dioxygenase may play a prominent role in
206 rs such as TGF-beta, CTLA-4, PD-1, ICOS, and indoleamine 2,3-dioxygenase play an important role in im
208 FN-gamma synthesis by donor T cells inducing indoleamine 2,3-dioxygenase synthesis by donor pDCs limi
209 ending on IFNgamma signaling and mediated by indoleamine 2,3-dioxygenase to a constitutive mechanism
212 explants was markedly reduced when placental indoleamine 2,3-dioxygenase was stimulated with interfer
213 a number of suppressive enzymes, among which indoleamine 2,3-dioxygenase was sufficient to inhibit an
214 ic cell accumulation, expression of IL-2 and indoleamine 2,3-dioxygenase were evident in TLR4 compare
215 n (which is a known competitive inhibitor of indoleamine 2,3-dioxygenase) is a competitive inhibitor
216 ence of interferon-gamma (known to stimulate indoleamine 2,3-dioxygenase) tryptophan but not threonin
217 also inhibited PIV3, including IFITM1, IDO (indoleamine 2,3-dioxygenase), PKR (protein kinase, RNA a
219 n-gamma-induced degradation of tryptophan by indoleamine 2,3-dioxygenase, activates the previously or
220 e, is similar to that of the large domain of indoleamine 2,3-dioxygenase, an enzyme that catalyzes th
221 g induction was mediated by DC expression of indoleamine 2,3-dioxygenase, and was confirmed in IDO-KO
224 ed during tryptophan metabolism initiated by indoleamine 2,3-dioxygenase, is known to induce T cell d
225 ane vesicles as part of a study on placental indoleamine 2,3-dioxygenase, the L-tryptophan-catabolisi
226 ophan limitation mediated by the host enzyme indoleamine 2,3-dioxygenase, which converts l-tryptophan
227 and primarily dependent on pDC expression of indoleamine 2,3-dioxygenase, which was induced through t
228 munodeficiency virus (HIV) infection-induced indoleamine 2,3-dioxygenase-1 (IDO) expression in activa
232 ols, whereas level of messenger RNA encoding indoleamine 2,3-dioxygenase-1 was significantly increase
233 sistent with a common reaction mechanism for indoleamine 2,3-dioxygenase-catalyzed oxidation of trypt
234 ance of L-tryptophan transport for placental indoleamine 2,3-dioxygenase-mediated degradation of L-tr
235 nts both BCH and 1-methyl-tryptophan inhibit indoleamine 2,3-dioxygenase-mediated L-tryptophan degrad
236 e trophoblast to be a rate-limiting step for indoleamine 2,3-dioxygenase-mediated L-tryptophan degrad
237 his mechanism is dependent both on placental indoleamine 2,3-dioxygenase-mediated tryptophan degradat
238 cyte division was specifically suppressed by indoleamine 2,3-dioxygenase-mediated tryptophan depletio
248 including those combining PD1 blockade with indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase (
249 of various tumor-promoting genes, including indoleamine 2,3-dioxygenase; and attenuation of these ch
250 uman (hIDO) and Shewanella oneidensis (sIDO) indoleamine 2,3-dioxygenases, Xanthomonas campestris (Xc
251 oring of tryptophan (trp) metabolism through indoleamine 2.3-dioxygenase (IDO) has been previously pr
252 FN-gamma, which stimulated the expression of indoleamine-2,3-dioxegenase (IDO) 1, an immune regulator
253 levels of immune-inhibitory IL-10, IL12p40, indoleamine-2,3-dioxidase, and TIMP-1 (tissue inhibitor
254 proved SB transposon encoding the human gene indoleamine-2,3-dioxygenase (hIDO), an enzyme that posse
255 uced inducible nitric oxide synthase (iNOS), indoleamine-2,3-dioxygenase (IDO) and heme oxygenase (HO
259 t levo-1-methyl tryptophan (L-1MT) can block indoleamine-2,3-dioxygenase (IDO) expressed by human den
260 the tumor tissue by the rate-limiting enzyme indoleamine-2,3-dioxygenase (IDO) expressed in tumor cel
261 yptophan pools by gamma interferon-inducible indoleamine-2,3-dioxygenase (IDO) is believed to be the
263 roids augment MSC expression and activity of indoleamine-2,3-dioxygenase (IDO), a primary mediator of
265 m the induction of type I IFN-alpha/beta and indoleamine-2,3-dioxygenase (IDO)-mediated immunosuppres
269 al burdens than control mice, underexpressed indoleamine-2,3-dioxygenase (Ido1) in lung endothelium a
270 in the promoter region of the gene encoding indoleamine-2,3-dioxygenase (IDO1) was found to be assoc
271 we show that untreated PDACs express minimal indoleamine-2,3-dioxygenase (IDO1); however, GVAX therap
272 cells, possibly via stimulation of host cell indoleamine-2,3-dioxygenase activity, in a dose-dependen
273 ot reverse tolerance, but treatment with the indoleamine-2,3-dioxygenase antagonist 1-methyltryptopha
274 ne (l-Kyn), which is supplied by a dedicated indoleamine-2,3-dioxygenase NanC encoded in the gene clu
275 w) phenotype, expressed the immunomodulatory indoleamine-2,3-dioxygenase, and upregulated expression
276 expression of tolerogenic mediators, such as indoleamine-2,3-dioxygenase, arginase, and TGF-beta, and
277 tor-kappaB, as well as the metabolic enzyme, indoleamine-2,3-dioxygenase, which breaks down tryptopha
278 Elevated betaDG correlated positively with indoleamine-2,3-dioxygenase-1 enzyme activity, regulator
282 results demonstrate a role for induction of indoleamine-2,3dioxygenase in accelerating the local for
284 nicotinamide adenine dinucleotide, retinol, indoleamines, and collagen provides crucial information
285 oxyl radicals exceeded that of melatonin, an indoleamine considered to be the most potent naturally o
286 enase involved in the degradation of several indoleamine derivatives and has been indicated as an imm
289 ve focused on three enzymes in this pathway: indoleamine dioxygenase (IDO1), kynurenine monooxygenase
293 actor in the production of catecholamine and indoleamine neurotransmitters and is also essential for
295 methyl-D-tryptophan, a specific inhibitor of indoleamine-pyrrole 2,3-dioxygenase (IDO), but not by NS
296 xidase subunits (p47(phox) or gp91(phox)) or indoleamine-pyrrole 2,3-dioxygenase 1 with or without an
297 mice deficient for p47(phox), gp91(phox), or indoleamine-pyrrole 2,3-dioxygenase 1, suggesting that A
298 , AngII markedly increased the expression of indoleamine-pyrrole 2,3-dioxygenase in parallel with inc
299 se systems, sometimes in comparison with the indoleamine serotonin (5-HT), on performance on a variet